Agency Forms Undergoing Paperwork Reduction Act Review, 16403-16404 [2017-06577]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices
potentially limiting the competitiveness
of the divested clinics. Third, to ensure
continuity of patient care and records as
the buyer implements its quality care,
billing, and supply systems, the Consent
Agreement requires DaVita to provide
transition services for a period up to
twenty-four months. Firewalls and
confidentiality agreements will prevent
the exchange of competitively sensitive
information. Fourth, the Consent
Agreement requires DaVita to provide
the buyer with a license to Renal
Ventures’ policies, procedures, and
medical protocols, as well as the option
to obtain and use DaVita’s medical
protocols, policies, and procedures, to
help with continuity of care for the
divested clinics’ patients.
The Consent Agreement requires
DaVita to provide notice to the
Commission prior to any acquisitions of
dialysis clinics in the markets addressed
by the Consent Agreement to ensure that
subsequent acquisitions do not
adversely impact competition in those
markets or undermine the remedial
goals of the proposed order. Finally, the
Consent Agreement allows the
Commission to appoint a monitor to
oversee DaVita’s compliance with the
Consent Agreement.
The purpose of this analysis is to
facilitate public comment on the
Consent Agreement, and it is not
intended to constitute an official
interpretation of the proposed Decision
and Order, or to modify its terms in any
way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2017–06556 Filed 4–3–17; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Elaine L. Baker,
Director, Management Analysis and Services
Office Centers for Disease Control and
Prevention.
Centers for Disease Control and
Prevention
[FR Doc. 2017–06537 Filed 4–3–17; 8:45 am]
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) GH17–002, Program
Development and Research to Establish
and Evaluate Innovative and Emerging
Best Practices in Clinical and
Community Services through the
President’s Emergency Plan for AIDS
VerDate Sep<11>2014
16:21 Apr 03, 2017
Jkt 241001
Relief (PEPFAR); GH17–003,
Conducting Public Health Research in
South Africa; and GH17–004,
Conducting Public Health Research
Activities in Egypt.
Times and Dates: 9:00 a.m.–2:00 p.m.,
EDT, April 25, 2017 (Closed), 9:00 a.m.–
2:00 p.m., EDT, April 26, 2017 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Program Development and Research to
Establish and Evaluate Innovative and
Emerging Best Practices in Clinical and
Community Services through the
President’s Emergency Plan for AIDS
Relief (PEPFAR), FOA GH17–002;
‘‘Conducting Public Health Research in
South Africa’’, FOA GH17–003,; and
‘‘Conducting Public Health Research
Activities in Egypt’’, FOA GH17–004.
Contact Person for More Information:
Hylan Shoob, Scientific Review Officer,
Center for Global Health (CGH) Science
Office, CGH, CDC, 1600 Clifton Road,
NE., Mailstop D–69, Atlanta, Georgia
30033, Telephone: (404) 639–4796.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–17–17AX]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
16403
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
Mobile Messaging Intervention to
Present New HIV Prevention Options for
Men Who have Sex with Men (MSM)
Study—New—National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Public health approaches to HIV
prevention and control are increasingly
complex for men who have sex with
men (MSM), a population with a
disproportionately high burden of HIV
infection. In addition to the established
biomedical treatments for HIV-positive
MSM, and behavioral strategies to
reduce the risk of transmitting or
contracting HIV, current
recommendations incorporate the
breakthrough biomedical risk reduction
E:\FR\FM\04APN1.SGM
04APN1
16404
Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices
strategy of pre-exposure prophylaxis
(PrEP) for HIV-negative MSM who are at
high risk of contracting HIV. For
maximum efficacy, health
communications about HIV prevention
and control should be delivered to MSM
according to their HIV serostatus and
risk category.
The National Center for HIV/AIDS,
Viral Hepatitis, STD and TB Prevention
is requesting approval to evaluate the
efficacy of a smartphone-based HIV
prevention intervention for MSM,
known as M3(M-Cubed) that has been
designed to deliver targeted messages in
six intervention domains: HIV testing,
sexually transmitted infection (STI)
testing, PrEP, antiretroviral (ARV)
treatment, Condoms, and Engagement in
Care. The smartphone and tablet
application includes 36 core messages
and 12 videos that were developed
based on CDC-sponsored iterative
formative research (OMB No. 0920–
0840) and a review of HIV health
communications literature. Messages
will be delivered to each participant’s
device. The proposed study will assess
whether exposure to the messagedelivery platform results in
improvements in participants’ selfreported sexual health and HIV
prevention behaviors, beliefs and
attitudes. Information will be collected
at baseline and 3-month, 6-month, and
9-month follow-ups.
The study population will include
1,206 adult MSM living in Atlanta, GA,
Detroit, MI and New York City, NY.
These study sites were selected not only
because they have high rates of HIV, but
also because significant disparities in
HIV among men who have sex with men
(MSM) have been observed by race/
ethnicity and age. Study participants
will be sexually active MSM at least 18
years in age who own and use and
Android and iOS smartphone. Study
participants will be stratified by risk
category: HIV positive (one third) and
HIV negative (one third each:
condomless anal sex in past three
months; no condomless anal sex past
three months). Across the three sites, we
will ensure that at least 40% of
participants are people of color (nonwhite or Hispanic) by quota sampling.
Participants will be recruited to the
study through a combination of
approaches, including online
advertisement, traditional print
advertisement, referral, in-person
outreach, and through word of mouth.
Participants will be randomly assigned
to an intervention group or a waitlist
control group. The control group will
receive the intervention after the study
has been completed.
A quantitative assessment
questionnaire will be administered
online at four points in time. The
assessment will be used to measure
changes in condom use behavior,
number of sex partners, HIV testing,
sexually transmitted disease (STD)
testing, health care engagement, preexposure prophylaxis uptake and
adherence, and antiretroviral therapy
uptake and adherence following
completion of the intervention.
Participants will complete the
assessment in-person at baseline and 9months, using a computer in a private
location, and remotely via their personal
computer or tablet device at the 3month and 6-month follow-ups. The
same information will be collected from
all participants. The burden per
response for each assessment is 1.5
hours.
It is expected that 50% of men
screened will meet study eligibility and
provide contact information, that 75
percent will schedule and show up for
an in-person appointment, and that 95
percent of these men will remain
eligible after reverification. We expect
the initial screening to take
approximately four minutes to
complete, that providing contact
information will take 1 minute, and the
rescreening prior to study enrollment to
take another four minutes.
OMB approval is requested for two
years. Participation is voluntary and
there are no costs to the respondents
other than their time. The total
estimated annual burden is 3,787 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses
per
respondent
Average
burden per
response
(in hours)
Type of respondent
Form name
Men ≥ 18 Years of Age Who Have Sex With
Men.
Participant Screening (Eligibility) ...................
1,693
1
4/60
Contact Information Form ..............................
Participant Screening (Verification) ................
Assessment ....................................................
847
635
603
1
1
4
1/60
4/60
1.5
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2017–06577 Filed 4–3–17; 8:45 am]
asabaliauskas on DSK3SPTVN1PROD with NOTICES
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) DP17–001, Community
Characteristics Associated with
VerDate Sep<11>2014
16:21 Apr 03, 2017
Jkt 241001
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Geographic Disparities in Diabetes and
Cardiometabolic Health.
Times and Dates:
10:00 a.m.–6:00 p.m., EDT, April 25,
2017 (Closed)
10:00 a.m.–6:00 p.m., EDT, April 26,
2017 (Closed)
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
E:\FR\FM\04APN1.SGM
04APN1
]]>Agencies
[Federal Register Volume 82, Number 63 (Tuesday, April 4, 2017)]
[Notices]
[Pages 16403-16404]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06577]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-17-17AX]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the following information collection request to the Office of
Management and Budget (OMB) for review and approval in accordance with
the Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (c) Enhance the quality, utility, and clarity of
the information to be collected; (d) Minimize the burden of the
collection of information on those who are to respond, including
through the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology, e.g., permitting electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Written comments and/or
suggestions regarding the items contained in this notice should be
directed to the Attention: CDC Desk Officer, Office of Management and
Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written
comments should be received within 30 days of this notice.
Proposed Project
Mobile Messaging Intervention to Present New HIV Prevention Options
for Men Who have Sex with Men (MSM) Study--New--National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers
for Disease Control and Prevention (CDC).
Background and Brief Description
Public health approaches to HIV prevention and control are
increasingly complex for men who have sex with men (MSM), a population
with a disproportionately high burden of HIV infection. In addition to
the established biomedical treatments for HIV-positive MSM, and
behavioral strategies to reduce the risk of transmitting or contracting
HIV, current recommendations incorporate the breakthrough biomedical
risk reduction
[[Page 16404]]
strategy of pre-exposure prophylaxis (PrEP) for HIV-negative MSM who
are at high risk of contracting HIV. For maximum efficacy, health
communications about HIV prevention and control should be delivered to
MSM according to their HIV serostatus and risk category.
The National Center for HIV/AIDS, Viral Hepatitis, STD and TB
Prevention is requesting approval to evaluate the efficacy of a
smartphone-based HIV prevention intervention for MSM, known as M\3\(M-
Cubed) that has been designed to deliver targeted messages in six
intervention domains: HIV testing, sexually transmitted infection (STI)
testing, PrEP, antiretroviral (ARV) treatment, Condoms, and Engagement
in Care. The smartphone and tablet application includes 36 core
messages and 12 videos that were developed based on CDC-sponsored
iterative formative research (OMB No. 0920-0840) and a review of HIV
health communications literature. Messages will be delivered to each
participant's device. The proposed study will assess whether exposure
to the message-delivery platform results in improvements in
participants' self-reported sexual health and HIV prevention behaviors,
beliefs and attitudes. Information will be collected at baseline and 3-
month, 6-month, and 9-month follow-ups.
The study population will include 1,206 adult MSM living in
Atlanta, GA, Detroit, MI and New York City, NY. These study sites were
selected not only because they have high rates of HIV, but also because
significant disparities in HIV among men who have sex with men (MSM)
have been observed by race/ethnicity and age. Study participants will
be sexually active MSM at least 18 years in age who own and use and
Android and iOS smartphone. Study participants will be stratified by
risk category: HIV positive (one third) and HIV negative (one third
each: condomless anal sex in past three months; no condomless anal sex
past three months). Across the three sites, we will ensure that at
least 40% of participants are people of color (non-white or Hispanic)
by quota sampling. Participants will be recruited to the study through
a combination of approaches, including online advertisement,
traditional print advertisement, referral, in-person outreach, and
through word of mouth. Participants will be randomly assigned to an
intervention group or a waitlist control group. The control group will
receive the intervention after the study has been completed.
A quantitative assessment questionnaire will be administered online
at four points in time. The assessment will be used to measure changes
in condom use behavior, number of sex partners, HIV testing, sexually
transmitted disease (STD) testing, health care engagement, pre-exposure
prophylaxis uptake and adherence, and antiretroviral therapy uptake and
adherence following completion of the intervention. Participants will
complete the assessment in-person at baseline and 9-months, using a
computer in a private location, and remotely via their personal
computer or tablet device at the 3-month and 6-month follow-ups. The
same information will be collected from all participants. The burden
per response for each assessment is 1.5 hours.
It is expected that 50% of men screened will meet study eligibility
and provide contact information, that 75 percent will schedule and show
up for an in-person appointment, and that 95 percent of these men will
remain eligible after reverification. We expect the initial screening
to take approximately four minutes to complete, that providing contact
information will take 1 minute, and the rescreening prior to study
enrollment to take another four minutes.
OMB approval is requested for two years. Participation is voluntary
and there are no costs to the respondents other than their time. The
total estimated annual burden is 3,787 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondent Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Men >= 18 Years of Age Who Have Sex Participant Screening 1,693 1 4/60
With Men. (Eligibility).
Contact Information Form... 847 1 1/60
Participant Screening 635 1 4/60
(Verification).
Assessment................. 603 4 1.5
----------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2017-06577 Filed 4-3-17; 8:45 am]
BILLING CODE 4163-18-P
